Bringing the power of science to healthcare.
As a life sciences company, Sequenom (NASDAQ: SQNM) has a guiding vision: To improve healthcare by providing revolutionary genomic and genetic analysis solutions for the clinical research and molecular diagnostic markets.
What makes this vision a reality? Our deep commitment to "Quality of Science." For us, only the highest quality is acceptable. We accept nothing less in the science that supports every product and service we offer. From design and development to manufacturing and marketing of innovative technology, instrumentation and tests, "Quality of Science" is the common element in everything we do.
A wholly owned subsidiary of Sequenom, Inc. (formerly known as Sequenom Center for Molecular Medicine), providing best-in-class laboratory testing services with a focus on prenatal and ophthalmological diseases and conditions, including the market-leading MaterniT21™ PLUS noninvasive prenatal laboratory-developed test intended for use in pregnant women at increased risk for fetal aneuploidies.
A division of Sequenom, Inc. that provides technologies and tools for translational research, oncology, agricultural genomics and clinical diagnostics. Sequenom Bioscience's proprietary MassARRAY® System is a high-performance MALDI-TOF mass spectrometry-based DNA analysis platform that delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.